7 C
Tuesday, December 7, 2021

Biotest AG opens seventh plasma assortment centre in Czech Republic

- Advertisement -spot_imgspot_img
- Advertisement -spot_imgspot_img

DGAP-Information: Biotest AG / Key phrase(s): Miscellaneous
25.11.2021 / 07:00
The issuer is solely liable for the content material of this announcement.


Biotest AG opens seventh plasma assortment centre in Czech Republic

– 27 plasma assortment centres in Europe to make sure long-term plasma provide

Dreieich, 25 November 2021. Biotest has obtained the working license for its seventh plasma assortment centre in Czech Republic from the nation’s nationwide public well being authority SUKL. The centre is positioned within the historic a part of the South-Bohemian metropolis Strakonice in Artwork-Nouveau iconic home.

Within the state-of-the-art centre with 15 donor beds, donors can watch TV or use Wi-Fi whereas donating. The centre is open 6 days per week for 12 hours a day.

Biotest is continuous on its deliberate path to broaden its personal donation stations to be able to enhance its plasma assortment capability and creates 12 new jobs within the Czech Republic. The plasma from the extra centre might be used to help to future progress on the new manufacturing facility in Dreieich.

“We’re more than happy to open Strakonice, one other state-of-the-art plasma centre within the Czech Republic. A particular thanks to all our present and future plasma donors who proceed to donate at our centres in the course of the Covid-19 pandemic, making an necessary contribution to the manufacturing of beneficial plasma-based medicines. After all, our thanks additionally go to our devoted employees, with out whom a steady donation and provide of plasma wouldn’t be doable,” underlines Dr Frank Velte, Vice President Plasma Service Europe GmbH.

The collected plasma is processed completely at Biotest AG in Dreieich. Audits carried out often within the Czech Republic make sure that the excessive authorized and inside high quality necessities are met.

About human blood plasma
Human blood plasma is a uncooked materials used to supply plasma derived merchandise, that are used to deal with varied sicknesses of the immune system, the blood system, in addition to in emergency drugs. Biotest ranks as one of many world’s sixth largest plasma protein product manufacturing teams. Biotest is without doubt one of the world’s six largest producers of plasma protein merchandise.

About Biotest
Biotest is a supplier of plasma proteins and organic medicine. With a price added chain that extends from pre-clinical and medical improvement to worldwide gross sales, Biotest has specialised primarily within the areas of medical immunology, haematology and intensive care drugs. Biotest develops and markets immunoglobulins, coagulation components and albumin primarily based on human blood plasma. These are used for illnesses of the immune and haematopoietic programs. Biotest has greater than 1,900 staff worldwide. The strange and choice shares of Biotest AG are listed within the Prime Normal on the German inventory alternate.

IR contact
Dr. Monika Buttkereit
Telephone: +49-6103-801-4406
Mail: [email protected]

PR contact
Dirk Neumüller
Telephone: +49-6103-801-269
Mail: [email protected]

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Abnormal shares: securities’ ID No. 522720; ISIN DE0005227201
Desire shares: securities’ ID No. 522723; ISIN DE0005227235
Itemizing: Frankfurt (Prime Normal)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

This doc accommodates forward-looking statements on total financial improvement in addition to on the enterprise, earnings, monetary and belongings place of Biotest AG and its subsidiaries. These statements are primarily based on present plans, estimates, forecasts and expectations of the corporate and are thus topic to dangers and components of uncertainty that might end in important deviation of precise developments from anticipated developments. The forward-looking statements are solely legitimate on the time of publication. Biotest doesn’t intend to replace the forward-looking statements and assumes no obligation to take action.

25.11.2021 Dissemination of a Company Information, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely liable for the content material of this announcement.

The DGAP Distribution Providers embody Regulatory Bulletins, Monetary/Company Information and Press Releases.
Archive at www.dgap.de

Supply hyperlink

- Advertisement -spot_imgspot_img
Latest news
- Advertisement -spot_img
Related news
- Advertisement -spot_img